Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET. Interested parties can access the live webcast on Surrozen's website, with a replay available afterward.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, with applications in inflammatory bowel disease, hepatitis, eye diseases, and more. For further details, visit surrozen.com.
Details
News Market Reaction – SRZN
The recorded move for SRZN in the trading session of this news was -5.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, chief executive officer, will provide a company overview and a business update at Canaccord Genuity’s 41st Annual Growth Conference at 9:30 a.m. ET on Thursday, August 12. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.
About Surrozen
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.
Media Contact:
Ian Stone, Managing Director
CanaleComm
Tel.: (619) 518-3518
Email: ian.stone@canalecomm.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.